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Abstract
Objective
A breath-holding spell (BHS) is defined as an apnea attack following 
an initial stressful event like anger, sadness, and fear, a painful event 
like falling or head trauma or any stressful psychology event. This 
study was designed to assess the comparative efficacy of levetiracetam 
plus iron and iron alone in reducing the BHS frequency in children 
aged 6 months to 5 years. 
Materials & Method
This study was designed as a double-blinded randomized clinical 
trial. Sixty patients aged 6 months to 5 years were assigned into two 
groups, with the first group (A) receiving only iron and the second 
group (B) receiving levetiracetam plus iron. At the end of the study, 
the efficacy of therapy was analyzed comparatively in these groups. 
Results
In this study, the mean number of attacks was 3.94 ± 2.69 before 
treatment and 1.71 ± 1.99 after treatment in the group A, while it 
was 6.39 ± 5.7 before treatment and 0.37 ± 1.03after treatment in the 
group B. The mean number of attacks after treatment was lower in 
group B than in group A. In fact, there was a significant difference 
between the two groups in terms of the number of attacks after 
treatment (P = 0.003). 
Conclusion
Levetiracetam plus iron is more effective than iron alone in reducing 
BHSs in children aged 6 months to 5 years. 
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Introduction
A breath-holding spell (BHS) is defined as an 
attack following an initial stressful event such as 
anger, grief, and fear, a painful stimulus such as 
falling and head trauma, or any other psychological 
distress (1, 2). During these attacks, the child starts 
crying in less than 11 seconds of initial stress, 
and after a deep inhalation, stops breathing in 
the exhalation stage, causing facial changes of 
either cyanosis or pallor. Attacks are sudden and 
involuntary with benign and self-limited nature, 
but careful consideration should be given to rule 
out any serious problem (3, 4).
The age of the onset of BHS is 11.6 months. 
However, it may occur before 6 months, and in 
about 11% of cases, the first attack occurs after 
2 years of age. Attacks decrease after 2 years of 
age, and until the age of 4, 11% of children will be 
attack free; almost all patients will recover by the 
age of 7. In the majority of articles, the gender of 
children studied showed a male to female ratio of 
more than one (5). 
The pathophysiology of attacks is a complicated 
process and is not yet fully discovered. Various 
studies have been conducted to examine the exact 
cause and the nature of attacks, and each of them 
presented a separate mechanism. Some studies on 
the pathophysiologic mechanism suggested that 
the underlying cause of breath-holding attacks was 
the irregularity of the autonomic nervous system 
(6, 7). In one study on the autonomic nervous 
system activity, ECG changes such as heart rate, 
frequency, and length of QT interval during an 
attack were recorded. The presence of disorders of 
the respiratory sinus rhythm and long systole was 
noticed during the attack, indicating the presence 
of a disorder in the regulation of the autonomic 
nervous system (8).
Iron deficiency is the most common cause of 
anemia in the first 2 years of life, a period which 
can be observed as the BHS peak in children. Some 
studies have shown that anemia or low levels of 
red blood cells may be an etiologic factor, and 
iron supplements may improve BHS in children 
(9-11). Levetiracetam is a new antiepileptic drug 
that is structurally similar to piracetam, which 
has been used in the treatment of BHSs. Previous 
studies have suggested that piracetam is an anxiety 
stabilizing agent, and thus, improves BHSs (12, 
13). Levetiracetam has fast and complete digestive 
absorption, but its protein binding is small. The 
drug and its metabolites are excreted through the 
urine and have a half-life of about 6-8 hours. The 
drug does not interact with other antiepileptic drugs, 
and also, does not affect the pharmacokinetics of 
other drugs such as contraceptive drugs, digoxin, 
and warfarin. It is used as an adjunct to control 
general and partial epilepsy. The exact mechanism 
of levetiracetam is still unknown, but its side 
effects are extremely small and do not require any 
controlled testing (14, 15). According to limited 
reports regarding the use of new pharmacological 
methods and the traditional method of using an iron 
to control BHSs, we designed and implemented this 
study to evaluate the efficacy of levetiracetam in 
combination with iron supplementation compared 
with iron therapy alone in controlling BHSs.
Materials & Method
In this randomized clinical trial, 60 6-month to 
5-year-old patients with BHS admitted to the 
Motahari Hospital of Urmia were enrolled from 16 
Oct 2018 to 18 Feb 2019. The exclusion criteria 
were neurodevelopmental delay, any disorder 
of the nervous system, and discontinuation of 
medication during the study. 
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The patients were randomly assigned into two 
groups: the first group (A) received only iron 
supplement at a dose of 5 mg/kg/day (from ferrous 
sulfate in two divided doses) for three months 
and the second group (B) started levetiracetam 
at a dose of 10 mg/kg/ day titrating to 40 mg/
kg/day (at two doses of Cobel Darou company) 
and iron at a dose of 5 mg/kg/day (from ferrous 
sulfate in two divided doses) for three months. All 
information needed for the research about age, sex, 
and number of attacks before and after treatment 
was gathered monthly through follow-up visits 
and over telephone and entered in checklists for 
final analysis. The data were analyzed using SPSS 
version 22 and reported using descriptive statistics 
(frequency and percentage) and mean ± standard 
deviation (mean ± SD). A Student’s t-test was used 
to analyze quantitative data and the Chi-square test 
to analyze the qualitative variables (and Fisher’s 
exact test if required). The data were also evaluated 
using the Kymograph-Smirnov test. The ANOVA 
test was used in case the data distribution was 
normal, and the Mann–Whitney U test was used 
to analyze non-parametric data. P-value <0.05 was 
considered statistically significant.
Ethical considerations
Agreement of the University’s Ethics Committee 
was obtained. Ethical considerations Agreement 
of Urmia university of medical sciences Ethics 
Committee was obtained
(code: IR.UMSU.REC.1397.321). The patients’ 
dignity was prioritized.
 All data of the patients were confidential.
Conscious informed consent was obtained from 
the infants’ parents.
Results
This study was conducted on 60 patients with BHS 
admitted to the Shahid Motahari Hospital in Urmia 
from 16 Oct 2018 to 18 Feb 2019. The patients 
were divided into two treatment groups: group A 
with 28 people receiving ferrous sulfate and the 
group B with 32 patients receiving ferrous sulfate 
and Levetiracetame (levebel). The mean ages were 
19.6 ± 10.32 months and 17.06 ± 8.46 months in 
the groups A and B, respectively, with the overall 
mean age being 18.25 ± 9.38 months. The mean 
hemoglobin was 10.86 ± 0.99 in the group A and 
10.85 ± 0.87 in the group B, and 10.86 ± 0.92 in 
total. The mean ferritin was 24.65 ± 7.63, 25.02 ± 
5.56, and 24.85 ± 6.55 for the group A, the group 
B, and as the total value, respectively (Tables 1 and 
2). There was no significant difference between 
the two groups regarding age, HB, and ferritin 
based on the Mann-Whitney U non-parametric test 
results (Table 2).
Group A consisted of 17 boys and 11 girls compared 
to group B with 11 boys and 21 girls, making an 
overall of 28 boys and 32 girls (Table 3-3). There 
was a significant correlation between the two 
groups in terms of gender according to the Chi-
square test results (P = 0.46); although, its severity 
was low based on the Cramer’s V test results, with 
the therapeutic effect being higher in the girls.
The mean number of attacks before and after 
treatment was 4.39 ± 2.69 and 1.71 ± 1.99 in the 
group A and 6.39 ± 5.07 and 0.37 ± 1.03 in the 
group B, respectively. The overall mean number of 
attacks was 4.75 ± 5.75 and 1.68 ± 1.68 before and 
after treatment, respectively (Tables 4 and 5). 
The mean number of attacks was lower in group B 
than in group A. In fact, there was no significant 
difference between the two groups in terms of attacks 
before a treatment based on the Mann-Whitney U 
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non-parametric test results (P = 0.072). However, 
there was a significant difference between the 
two groups regarding the number of attacks after 
treatment (P = 0.003). Thirteen (46.4%) and 15 
(53.6%) patients in group A experienced repeated 
attacks and no attacks compared to four (12.5%) 
and 28 (87.5%) patients in group B, respectively. In 
general, 17 patients (28.3%) experienced repeated 
attacks, while 43 patients (71.7%) did not have 
further attacks (Table 5, Figure 6).
BHS is defined as an attack following an initial 
stressful event such as anger, grief, and fear, a 
painful stimulus such as falling and head trauma, or 
any other psychological distress (1). Iron deficiency 
is the most common cause of anemia in the first 2 
years of life, a period which can be observed as the 
BHS peak in children. Some studies have shown 
that anemia or low levels of red blood cells may 
be an etiologic factor, and iron supplements may 
improve BHS in children (9, 10)¸ Levetiracetam is 
a new antiepileptic drug that is structurally similar 
to piracetam, which has been used in the treatment 
of BHSs. Previous studies have suggested that 
piracetam is an anxiety stabilizing agent, and 
therefore, improves BHSs (12). Levetiracetam 
has fast and complete digestive absorption, but 
its protein binding is small. It is metabolized with 
the hydrolysis of the enzyme, but is independent 
of the P450 cytochrome system. The drug and its 
metabolites are excreted through the urine and 
have a half-life of about 6-8 hours. The drug does 
not interact with other antiepileptic drugs, and 
also, does not affect the pharmacokinetics of other 
drugs such as contraceptive drugs, digoxin, and 
warfarin. It is used as an adjunct to control general 
and partial epilepsy. The exact mechanism of 
levetiracetam is still unknown, but its side effects 
are extremely small and do not require any testing 
(14). This study was conducted on 60 patients with 
BHS admitted to the Shahid Motahari Hospital of 
Urmia to examine the efficacy of the combination 
of Levebel and iron compared to iron alone in 
two treatment groups: group A with 28 patients 
receiving only ferrous sulfate and group B with 
32 patients receiving ferrous sulfate and Levebel. 
Group A consisted of 17 boys and 11 girls, and the 
group B consisted of 11 boys and 21 girls, with 
the overall participants being 28 boys and 32 girls. 
The mean age was 19.60 ± 10.32 months in group 
A and 17.06 ± 8.46 months in group B with the 
overall mean age of 18.25 ± 9.38 months. The mean 
number of attacks after treatment was 37 ± 1.03 
in group B and 71 ± 1.99 in group A. There was 
no significant difference between the two groups 
concerning attacks before a treatment based on the 
Mann-Whitney U non-parametric test results (P = 
0.072). However, there was a significant difference 
between the groups regarding attacks after 
treatment (P = 0.003). Thirteen patients (46.4%) in 
group A experienced repeated attacks compared to 
four patients (12.25%) in group B.
Moreover, 15 patients in group A (53.6%) 
experienced no attacks compared to 28 patients 
(87.5%) in group B. In a study conducted by Mocan 
et al. (2000) in Turkey to assess the effect of iron 
supplementation on BHSs after three months, there 
was a significant difference between iron-treated 
children and controls (84.1% vs. 21.4%) regarding 
the reduction of cyanotic spells. They concluded 
that treatment for iron deficiency anemia was 
effective in reducing the frequency of BHS (16). 
However, this is not consistent with the result of 
our study showing a response rate of only 54% in 
those treated with iron alone. In a study conducted 
by Azam et al. (2008) in Pakistan, the effect of 
prophylactic piracetam was examined on severe 
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cases of BHS. The spells completely disappeared 
in 81% of children, and the number of attacks 
decreased to less than one per month with less 
severity in 9% of them. Prophylaxis was given for 3 
to 6 months (average of 5 months). They concluded 
that piracetam was effective in preventing severe 
BHS (17). Considering the similarity of the 
chemical structure of levotiracetame to that of 
piracetam, the findings of their study are consistent 
with those of our study. In another study conducted 
by Ashraf Zadeh et al. (2005) in Iran, the effect of 
piracetam was examined on BHS. They reported 
that 19 (90.5%) of the children receiving piracetam 
had a good response, while in the group receiving 
the placebo, only eight children (40%) experienced 
no attacks (P = 0.002). The incidence of clinical 
complications was similar in both groups. They 
concluded that piracem was an effective medication 
for the treatment of childhood BHS, with no major 
side effects (18), which is consistent with the 
results of our study. Some previously published 
studies examined the effect of piracetam and 
iron in comparison with iron alone on controlling 
BHS (19, 20). These studies reported a significant 
difference between the two groups concerning the 
frequency reduction of attacks (P=0.001), with the 
mean number of attacks being one spell in a month 
in the first group and two attacks in the second 
group. They concluded that treating spells with 
the combination of piracetam and iron was more 
effective than only with iron, which is compatible 
with the findings of our study.














Mean 19.60 10.27 45.76 10.86 24.65
SD 10.32 1.53 1.86 0.99 7.63
minimum 6 8 43 8/90 12
maximum 42 14 50 12/90 47
B 32
Mean 17.06 10.25 45.62 10.85 25.02
SD 8.46 2.17 1.85 0.87 5.56
Minimum 6 6/70 43 8/20 15
Maximum 47 16 49 12/10 38
P-value 0.381 0.613 0.812 0.682 0.634
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Table 2. The mean age, weight, head circumference, Hb, ferritin for all patients.
Age Weight Head circumference Hb Ferritin
Mean 18.25 10.26 45.69 10.86 24.85
SD 9.38 1.88 1.84 0.92 6.55
Minimum 6 6.70 43 8.20 12
Maximum 47 16 50 12.90 47
P- Value 0.381 0.613 0.822 0.682 0.634








number 17 11 28
0.047
percentage 60.7% 39.3% 100%
B
number 11 21 32
percentage 34.4% 65.6% 100%
Total
percentage
number 28 32 60
46.7% 53.3% 100%
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Repeat attacks Yes Number 13 4 17
Percentage 46.4% 12.5% 28.3%
No Number 15 28 43
Percentage 53.6% 87.5% 71.7%
Total
Percentage
Number 28 32 60
100% 100% 100%
Figure 1. The mean of age, weight, head circumference,Hb, ferritin for Group A
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Figure 2. The mean of age, weight, head circumference,Hb, ferritin for Group B
Figure 3. Distribution of gender in the treatment group
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Figure 4. The mean age number of attacks Group A
Figure 5. The mean number of attacks in group B
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In Conclusion
Based on the findings of our study, we suggest 
that the combination of levetiracetam and iron is 
more effective than iron alone in controlling BHSs. 
Being a safe pharmaceutical profile in children, 
levetiracetam can be safely used to control BHS in 
combination with iron. 
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